Eisai Test Shows Halaven, Roche Drug Equal For Breast Cancer Spread
This article was originally published in PharmAsia News
Executive Summary
Eisai said its Halaven (eribulin) for treating breast cancer that has spread performed no better than Roche's Xeloda (capecitabine).